SABCS2025

Home Tag

Balmaña - Pimentel VHIO

RADIOLA study identifies a new complementary biomarker to distinguish which metastatic gBRCA, HER2- breast cancer patients are molt likely to respond up to 7 times more to olaparib.

Promoted by SOLTI and developed in scientific collaboration with the Vall d’Hebron Institute of Oncology (VHIO), the SOLTI-1910 RADIOLA study…

Meritxell Bellet VHIO

The PremiÈRe study positions elacestrant as a promising drug for the treatment of breast cancer in young women diagnosed during premenopause

The Phase 2 clinical trial PremiÈRe (SOLTI-2104) is the first to evaluate the oral drug elacestrant -either alone or combined…